Nisa Investment Advisors, LLC Eagle Pharmaceuticals, Inc. Transaction History

Nisa Investment Advisors, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 02, 2023	SELL	$15.21 - $22.88 $18,860 - $28,371	-1,240 Reduced 75.15%	410 $6,000
Q2 2023 Aug 11, 2023	BUY	$17.74 - $31.87 $21,997 - $39,518	1,240 Added 302.44%	1,650 $32,000
Q3 2022 Nov 07, 2022	SELL	$26.42 - $47.12 $5,468 - $9,753	-207 Reduced 33.55%	410 $13,000
Q2 2022 Aug 03, 2022	BUY	$41.26 - $51.35 $2,888 - $3,594	70 Added 12.8%	617 $27,000
Q1 2022 Apr 29, 2022	SELL	$44.58 - $52.6 $113,144 - $133,498	-2,538 Reduced 82.27%	547 $27,000
Q4 2021 Feb 03, 2022	BUY	$45.82 - $56.9 $2,291 - $2,845	50 Added 1.65%	3,085 $142,000
Q3 2021 Oct 18, 2021	SELL	$43.79 - $55.78 $62,926 - $80,155	-1,437 Reduced 32.13%	3,035 $169,000
Q2 2021 Aug 06, 2021	SELL	$36.86 - $44.5 $36,860 - $44,500	-1,000 Reduced 18.27%	4,472 $191,000
Q4 2020 Jan 25, 2021	BUY	$41.72 - $51.34 $129,248 - $159,051	3,098 Added 130.5%	5,472 $255,000
Q3 2020 Oct 20, 2020	BUY	$37.02 - $51.28 $87,885 - $121,738	2,374 New	2,374 $101,000

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Nisa Investment Advisors, LLC with notifications on news.